U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07565493) titled 'Psilocybin Administration With 5-HT1a Blockade' on April 27.
Brief Summary: The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG). Further, the investigators will assess the effects of psilocybin on post-acute sleep and dreaming through the use of sleep EEG and sleep and dream diaries.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Psychedelic Effects in Healthy Volunteers
Intervention:
DRUG: Pindolol
Pindolol is a 5-HT1A antagonist drug that will be used ...